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The aim of the present study was to evaluate the correlation between the end of an Oxford
sleep resistance (OSLER) test session and a neurophysiological marker of sleep onset in
Parkinson’s disease (PD) patients. Single center study was conducted in PD patients
with excessive daytime sleepiness [Epworth sleepiness scale (ESS) >9]. The OSLER test
was conducted with a concomitant electroencephalography (EEG), electromyography
(mentalis), right and left electroculogram, and video monitoring. Neurophysiological (NP)
sleep onset was defined according to AASM criteria (2005). Five PD patients with mean
ESS of 14 (10–16) were included. OSLER test duration was shorter than 40min in all
patients (mean duration 20min and 39 s). No patient fulfilled neurophysiological criteria to
sleep onset at the time of OSLER test termination. In 13 OSLER sessions that ended
before 40min, eight had microsleeps in the last 30 s before the end of the test. NP
monitoring showed signs of sleepiness in all patients. In PD patients, the early termination
of an OSLER test session may not correspond to NP criteria of sleep onset. However, in
all PD patients with abnormal OSLER results, there were EEG signs of sleepiness, which
do not exclude the potential utility of OSLER test to evaluate the risk of falling asleep.
Keywords: sleepiness, sleep onset, OSLER test, Parkinson’s disease
Introduction
It is well established that excessive daytime sleepiness (EDS) in Parkinson’s disease (PD) significantly
interferes with the patient’s quality of life and constitutes an important risk factor for accidents (1,
2). In clinical practice, the quantification of EDS and its relation, for instance, to driving fitness is
a critical issue and physicians increasingly need to screen patients at risk of sleep-related accidents.
However, the assessment of EDS is complex; complaints do not always coincide with an objective
impairment of vigilance (3), and patients often do not recognize they suffer the problem, which
increases largely several risks as those related to driving (4).
Several sleep scales have been used to evaluate PD sleep disorders, but only a small number
has been assessed specifically in a PD population (3, 5–13). The International Parkinson and
Movement Disorder Society recommends the Epworth sleepiness scale (ESS) (5) for use in PD
for daytime sleepiness based on a review of the validity and clinimetric characteristics of all
available sleep scales that have been applied to PD patients (13). Importantly, sleepiness scales as the
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ESS or Stanford sleepiness scale (SSS) (6) do not strongly correlate
with objective quantifications (14). Furthermore, specific PD-
related problems, such as the occurrence of motor symptoms
and fluctuations, fatigue, cognitive impairment, depression, and
medication side effects, may interfere with the validity of generic
sleep scales.
Assessing daytime impairment by using objective quantifica-
tion tools may provide a better evaluation of daytime function
changes in these patients. The standard objective tests of daytime
sleepiness are the multiple sleep latency test (MSLT) (14, 15) and
the maintenance of wakefulness test (MWT) (16). The MSLT
and MWT provide quantitative measures of daytime sleepiness
and ability tomaintain vigilance. Both tests are based on latency to
electroencephalographic sleep onset. However, the need for day-
time electroencephalography (EEG) monitoring and technician
attendance renders these tests labor intensive and expensive.
To overcome these difficulties, Bennett and Davies (17) pro-
posed a behavioral test, called the Oxford sleep resistance
(OSLER) test, which utilizes a computerized, non-assistedmethod
for monitoring wakefulness and detecting sleep onset. However,
failure or inability to cooperate can result in false positive results
in OSLER test. False positives may occur due to a patient’s lack
of attention, fatigue, motor impairment, and frequent eye blink-
ing. One way to overcome this limitation is to evaluate with a
concomitant neurophysiological study the moment that patients
stop pressing the button and verify if it corresponds to a true sleep
onset. The main objective of this study was to document if the
early end of an OSLER session in PD patients corresponds to true
sleep onset measured with neurophysiological recordings and to
support its validity as a measure to analyze the tendency to fall
asleep. A secondary objective was to verify if early terminations
were associated with clinical findings or other sleep-related EEG.
Materials and Methods
Patients
A convenience sample of five PD patients with 3 years of motor
symptoms and complaints of EDS were recruited from the Move-
ment Disorders Unit of the Lisbon University Hospital. Eligible
patients had a diagnosis of idiopathic PD (18), an ESS (5) score
10, and (in the investigators judgment) the capacity to perform
the evaluation tests. Non-eligibility criteria were Mini Mental
State Examination (MMSE) score <24 (19), clinical diagnosis of
depression or active psychosis, severe dyskinesia (UPDRS 32> 1
or 32> 1 in ON), treatment with hypnotics or psychotropics with
known sedative effects, or suffering from other medical diseases
known to cause daytime sleepiness (e.g., obstructive sleep apnea
or periodic limbmovement disorder). The presence of fatigue was
screened for using the 9-item fatigue severity scale (FSS) (20, 21)
and the presence of apathy was diagnosed according to Starkstein
and Leentjens diagnostic criteria (22–24) and quantified using the
14-item Apathy Scale (AS). All participants signed an agreement
to take part in the study. The studywas approved by the local ethics
committee.
Study Design
This study was conducted in a single center. Patients underwent
the usual OSLER protocol with four periods of a maximum of
40min OSLER session with an interval of 2 h in between. Patients
were instructed not to sleep between sessions and not to consume
alcohol, caffeine, chocolate, tea, hypnotics, or benzodiazepines for
12 h before the evaluation day and for the duration of the evalu-
ation procedures. A full night polysomnography (PSG) was per-
formed to exclude other sleep disorders known to cause daytime
sleepiness (according to American Sleep Disorders Association
criteria) (25).
Measurements
OSLER Test
The OSLER test consists of a 40-min sleep-resistance challenge
conducted in a dark and quiet room (17). It features a small light-
emitting diode (LED) in a wall-mounted box – and a patient-held
pressure-sensitive switch box, both attached to a control unit con-
nected to a computer. Lying down in a darkened room, patients
were asked to press the switch in response to the illumination
of the LED, which was set to occur every 3 s. The switch had
no audible click. Patients were asked to stay awake but not to
use active methods to keep themselves awake, such as singing,
shouting, or pinching themselves. A software program controlled
the LED and stored the responses. “Sleep onset” was defined
as missing seven presses, equivalent to 21 s of no response. The
investigator remained in the same darkened room as the patients,
in order to clinically monitor their behavior. Patients underwent
anOSLER test at 9:00 a.m., 11:00 a.m., 1:00 p.m., and 3:00 p.m. and
the sessionwas terminated after sleep onset was determined by the
OSLER or after 40min, whichever came first. The total score was
defined as the mean time to “sleep onset” over the four periods.
Electroencephalography
Electroencephalography was monitored during OSLER test using
F3/A2, F4/A1, C3/A2, C4/A1, O1/A2, O2/A1, two horizon-
tal electrooculographic channels (EOG R e L), and submental
electromyography (EMG). Neurophysiological sleep onset was
defined as the first epoch of 30 s scored as any stage other
than stage W (wakefulness) and stage N1 as alpha EEG waves
replaced by theta-frequency (4–7Hz) waves that occupy >50%
of the epoch; if alpha waves are not readily apparent, the pres-
ence of 4–7Hz waves with slowing of background activity by
at least 1Hz compared with stage W, vertex sharp waves, or
slow eye movements also can be used to document the start of
stage N1 (American Academy of Sleep Medicine). Microsleeps
were defined as a period of at least 3 s with a theta (4–7Hz)
rhythm replacing an alpha rhythm or appearing on a background
of desynchronized EEG on all EEG channels, and without eye-
blinking artifacts. Slow eye movements were accepted. No max-
imal duration was defined for microsleep, so that it could evolve
into established sleep if it lasted long enough.
Other Evaluations
The self-rated SSSwas used for rating sleepiness and tomeasure its
severity just before each OSLER test (6). The SSS is a seven-point
Likert-type scale where a high score indicates a high level of sleepi-
ness and patients were instructed to choose the set of descriptors
that best described his or her current feeling of sleepiness just
before each OSLER test.
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TABLE 1 | Clinical characteristics of patients.
1 2 3 4 5 Mean
Gender Male Male Male Male Male
Age (years) 62 72 56 64 58 62.4
PD duration (years) 3 4 10 4 7 5.6
UPDRS Total
(I+ II+
III+ IV)
39 76 50 47 56 53.6
Part III 26 49 36 31 32 34.8
Hoehn and Yahr 2 2 2 2 2 2
Epworth SS 10 16 15 14 15 14
Standorf SS 1 1 1 2 2 1.4
Apathy SS 34 43 35 33 38 36.6
Fatigue SS 20 53 21 23 23 28
In addition, on the day of the OSLER test with EEG records,
all patients were evaluated using the MDS-UPDRS (26) and the
Hoehn and Yahr (H&Y) scale (27) while in the ON-state.
Data Analysis
Data were analyzed using descriptive statistics and will be
expressed as the median or mean SD.
Results
Patients Clinical Characteristics
Patients (median age 62, range 56–72) included in this study had
a median PD duration of 4 years (range 3–7 years) and demon-
strated a broad range in UPDRS scores (total) (39–76). Screening
for fatigue and apathy found only one patient who met diagnostic
criteria for both (Patient 2). Individual patient data andmeans are
shown in Table 1.
Polysomnography
The full night ambulatory PSG performed in the night before the
OSLER test showed mild OSAS in one patient. No other relevant
respiratory disturbances or periodic limb movements were found
in the other patients (Table 2).
OSLER Test Results
The OSLER test duration was shorter than 40min in all the five
patients. However, no patient fulfilled neurophysiological criteria
to document sleep onset at the time of OSLER test termination.
Only one patient fell asleep while performing the OSLER test. In
this patient, there was waxing and waning alpha activity, fulfilling
the criteria to score N1 sleep stage even before the OSLER test
termination. Table 3 compares the sleep latencies of individual
sessions as defined by the OSLER test and the simultaneously
recorded EEG.
Although none of the patients fulfilled neurophysiological cri-
teria of sleep onset in the end of OSLER test, we found that in
13 of the 19 OSLER sessions that ended before 40min, 8 had
microsleeps in the last 30 s before the end of OSLER test (Table 4).
Furthermore, neurophysiologicalmonitoring showed othermark-
ers of sleepiness in all patients, such as slow eye movements and
increased blinking. One patient performed significant periods of
the test with their eyes closed.
TABLE 2 | Ambulatory polysomnography results.
Patients PSG
AHI PLMs ODI Hypnogram Conclusion
1 0:9 0 5:1 # Sleep efficiency+
sleep maintenance
insomnia+# REM
Without OSAS
or PLMDs
2 3:2 0 12:1 # Sleep efficiency+
initial and sleep
maintenance insomnia
Without OSAS
or PLMDs
3 10:4 0 15:1 Sleep maintenance
insomnia
Mild OSAS
4 0:3 2:9 10:4 # Sleep efficiency+
" awakenings
Without OSAS
or PLMDs
5 2:6 2:8 7:8 # Sleep efficiency+
sleep maintenance
insomnia
Without OSAS
or PLMDs
PSG, polysomnography; AHI, apnea/hypopnea index; PLMs, periodic limb movements;
ODI, oxygen desaturation index; OSAS, obstructive sleep apnea syndrome; PLMDs,
periodic limb movement disorders.
TABLE 3 | OSLER tests results with simultaneous neurophysiological
records.
Patients OSLER test (minutes) EEG
Mean sleep
latency
(normal
39.8min)
Sleep
latency
During all
OSLER test
Last 30 sec. of
OSLER test
1 00:25:50 00:39:09 Alert Wakefulness
00:01:24 Alert Wakefulness
00:22:48 Alert Wakefulness
00:40:00 Alert Wakefulness
2 00:04:06 00:02:09 00:00:08 (N1) Microsleep
00:01:21 00:00:10 (N1) Microsleep
00:05:27 00:00:41 (N1) Microsleep
00:07:27 00:00:14 (N1) Microsleep
3 00:36:37 00:26:27 Alert No EEG record
00:40:00 Alert Wakefulness
00:40:00 Alert Wakefulness
00:40:00 Alert Wakefulness
4 00:23:29 00:03:51 Alert Microsleep
00:40:00 Alert Wakefulness
00:10:03 Alert Wakefulness
00:40:00 Alert Wakefulness
5 00:13:12 00:16:33 Alert Microsleep
00:03:54 Alert Microsleep
00:07:54 Alert Microsleep
00:24:27 Alert Wakefulness
EEG, electroencephalogram; sec., seconds; N1, N1 stage of NREM sleep.
Discussion
Theoretically, the moment when patients stop pressing the switch
for 21 s is supposed to represent sleep onset, and previous studies
in non-PD populations have found that the OSLER test is capable
of discriminating between sleepy and normal individuals without
overlap (mean latency 10.5 and 39.8min, respectively) (17). We
have previously reported a study in which all sleepy PD patients
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TABLE 4 | Sensitivity of OSLER test for microsleeps.
Microsleep (+) Microsleep (–)
OSLER (+) 8 5 13
OSLER ( ) 0 6 6
8 11 19
OSLER (+), OSLER test ended before 40min; Microsleep (+), microsleep in the last 30 s
of the OSLER test.
Sensitivity of OSLER test for Microsleeps – 100%; specificity of OSLER test for
Microsleeps – 55%; positive predictive value – 62%; negative predictive value – 100%.
had an abnormal OSLER sleep latency (28). Now, we found no
correspondence between the end of the OSLER test sessions and
the documentation of true neurophysiological criteria for sleep
onset.
Nevertheless, all five sleepy PD patients hadOSLER sleep laten-
cies of <40min. Although we did not have a control group, previ-
ous studies in the literature show that this finding is abnormal. In
the studies conducted by Bennett (17) and Mazza (29), all control
subjects were able to finish the 40-min test without falling asleep.
If we apply another commonly used cut-off score for abnormality
(20min) (30), two of the five patients presented abnormal scores
in the OSLER test.
The neurophysiological criteria for sleep used in this study, are
the same that are used in MSLT and MWT, and requires the pres-
ence of theta rhythm in at least 50% of a 30 s epoch (that it, at least
15 s). These criteria have low sensitivity for sleepiness: sleepiness
begins even before reaching stage 1 NREM sleep. Furthermore,
there is no exactmoment of sleep onset – there are gradual changes
in behavior, reaction time, and cognitive function and physiolog-
ical changes. This stage has been coined as the “Pre-dormitum”
(31). It is defined as having behavioral signs such as heaviness and
drooping of the eyelids, clouding of the sensorium, and inability to
see, hear or perceive things in a rational or logical manner. There-
fore, the detection of microsleep has been described as a better
measure of sleepiness (32). Indeed, our study found that 62% of
the OSLER sessions with durations below 40min hadmicrosleeps
and the OSLER test showed a sensitivity and a negative predictive
value of 100% for microsleeps (Table 4). Furthermore, all patients
had neurophysiological (slow eye movements, increased blinking
rate) and behavioral sleepiness. Taken together, this suggests that
OSLER test termination in our PD patients is mainly caused by
sleepiness.
In their cross-sectional sleep laboratory study (n= 11), Krieger
and colleagues (30) verified that a sleep latency by OSLER test
and simultaneous measurement of EEG had excellent agreement
(ICC= 0.91) with a bias of – 0.97min (30) when sleep was defined
as episodes of sleep of 3 s duration, similarly to our microsleep
criteria. Therefore, OSLER test results in our PD population
appear to be less specific to detected microsleeps than in other
populations. In their study conducted in normal subjects, Priest
et al. (33) reported that only 2 of 37 OSLER test terminations
were not associated with microsleeps. The authors attributed
these results to lapses of attention and misunderstanding of the
test’s instructions. While the latter is unlikely in our patients (all
patients received detailed instructions prior to the tests), lapses
of attention are a possible contributing factor. It is noteworthy
that some of the patients showed performed parts of the OSLER
test while showing alpha rhythm in the EEG. Alpha bursts during
active tasks have been associated with attention lapses (34). In
addition, the higher number of false positive results in PD patients
could be related to disease specificity; for example, visual process-
ing deficits, frequent and slow eye blinking, or motor impairment
that leads to finger motion below levels detectable by the OSLER
system could have impacted on the test results. Although only
one of our patients met the criteria for apathy and fatigue, these
symptoms were not directly assessed at the time of the OSLER
session and cannot be ruled out. It should be noted that the only
patient whomet criteria for fatigue, apathy, and had also the worst
motor performance, and was the only patient who actually fell
asleep (EEG criteria) during OSLER test.
The patient who fell asleep according to neurophysiological
criteria did it in the first minute of the test. However, he was
able to perform the OSLER test for a mean duration of 4min and
6 s. This is in line with other studies and indicates that automatic
behavior is still possible in the transition fromwakefulness to sleep
(35). It is important to note that the OSLER test is only finished
when seven consecutive presses are missed. In the study of Priest
et al. (33), 25 out of 57 epochs of sleep (defined as a microsleep
with more than 15 s) led to 2–6 consecutive missed responses
therefore allowing the test to continue. The authors of that study
suggested that the inclusion of the error rate during the test might
increase the sensitivity of the OSLER test to detect microsleeps,
as the possibility to detect microsleeps increases in parallel with
the number of consecutive lapses. This approach as been later
replicated in a study of sleepyOSAS patients and controls andmay
be useful to try in future PD studies (29).
We used ESS for screening for sleepiness in PD patients as
recommended by the International Parkinson and Movement
Disorder Society but it has recognized limitations. Some stud-
ies using ESS have shown best correlation for pathological day-
time sleepiness with a higher cut-off point (>14). So, it will
be important to look for different results using different cut-off
points in future studies using OSLER test (36). Also, although
we used video recording simultaneously to OSLER test for eval-
uation of motor performance it was not possible to rule out
with absolute certainty all the motor phenomena that could
compromise test performance. Additionally, it would have been
useful to compare the OSLER results with MWT in order to
validate OSLER test as a measure to resist sleep. Finally, we
should emphasize that the PD population often has transient
abnormalities in the baseline EEG (notably slow activity, like
theta bursts), which are common and do not necessarily mean
sleepiness. It is not entirely possible to rule out that themicrosleeps
scored in this study are abnormal EEG transients. However, the
concomitant presence of other markers of sleepiness (slow eye
movements, increased blinking) (37, 38) in our patients sup-
ports our assumptions that the theta burst scored are in fact
microsleeps.
In conclusion, the results of this small study show that the
OSLER test in PD patients does not measure true time to
sleep onset. However, it seems to be a sensitive tool to detect
microsleeps in PD. Further studies are needed to find out the
clinical meaningfulness and usefulness of OSLER test in the deter-
mination of the tendency to fall asleep in patients with Parkinson
disease.
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